CESI-MS links CE to Mass Spec

A breakthrough technology solution introduced by AB Sciex LLC will help biopharmaceutical scientists to more accurately predict efficacy, reduce the time to market for new therapeutics and proactively detect potential issues before they lead to costly product recalls.

CESI marks a novel combination of capillary electrophoresis (CE) and electrospray ionization (ESI) technologies to create an integrated workflow solution which includes the industry’s first commercially available ultra low-flow separation and ESI module for biologics, along with a high-performance, high-resolution, accurate mass instrument that is ideal for biopharmaceutical development.The CESI-8000 system can be integrated with the AB Sciex TripleTOF ^R solution said to provide orthogonal and/or superior results compared to dual-method liquid chromatography / mass spectrometry-based approaches. 

From a single digest and run, users of CESI-MS gain the following: (a) Identity and Purity information with 100 percent coverage in a peptide map; (b) Heterogeneity information with ultrasensitive glycopeptide quantitation; and (c) Stability information identifying, deamination, cyclisation and oxidation ‒ all highly important to biopharmaceutical scientists.

The CESI 8000 system is the first CE-related product launch from AB Sciex. Expanding its portfolio of separations solutions, AB Sciex obtained the CESI technology through combining the CE business of Beckman Coulter Life Sciences with Eksigent nano and microscale chromatography to form a newly expanded separations business known as SCIEX Separations.